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The need for research in lung cancer is obvious when you look at cancer statistics. In 
Norway it is the 3
rd
 most common cancer by incidence, but beyond competition killer number 
one. Survival has improved markedly for many of our more prevalent cancers, illustrated by a 
national increase in 5-year survival for all cancers from around 40% to above 65% during the 
last 30 years. Disappointingly, lung cancer patients have not enjoyed a significantly improved  
prognosis today compared to 3 decades ago and the survival is poor (below 15% 5-year 
survival).(1) From years of clinical work with different cancers, advanced lung cancer has 
therefore marked me due to the gravity of this disease.  
Surgery, chemotherapy and radiotherapy have been the main pillars of cancer 
treatment. Some of the recent improvement in survival of other cancers can be attributed to 
novel treatment therapies. Such therapies increasingly target specific molecules involved in 
cancer progression and metastasis. Development and clinical introduction of targeted 
therapies takes several years. The important initial step is target definition. Experimental 
research continuously identifies new and potentially important molecules in cancer 
progression. The next step is to identify the significance of these molecules in different 
cancers. It must be determined to what extent the target is present in cancer. If present, a 
hypothesis of involvement in cancer progression can be claimed if the presence of the target is 
found to have a prognostic impact. Prognostication by molecular markers is also important as 
this may identify subgroups of patients in need for additional treatment or not, which 
traditional clinicopathological prognosticators have not been able to identify. 
In 2004 a translational research strategy in non-small cell lung cancer (NSCLC) was 
established at the University of Tromsø/University Hospital North Norway by my mentors, 
Professors Roy M. Bremnes and Lill-Tove Busund. Since, a continuous effort has resulted in 
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several publications and dissertations by our group. One of the early identified fields of 
interest was hypoxia and angiogenesis, which is the theme of this dissertation. 
The first paper in this dissertation report on the Hypoxia Induced Factors (HIFs) and 
some of the HIF controlled molecules in subgroups of histology. The HIFs were of great 
interest since they are at the heart of the adaptive mechanisms cancer cells must master for 
survival and proliferation.  
The second paper was directed more towards angiogenesis and report on the 
prognostic significance of the angiopoietins (Angs) 1, 2, 4, their receptor Tie-2 and co-
expression subgroups of Ang-2 and VEGF-A expression. We specifically wanted to look at 
subgroups as we have already published on VEGF-A in NSCLC and there is a close interplay 
between VEGF-A and angiopoietins in angiogenesis and there is targeted therapy against 
VEGF-A. 
The third paper shifted the focus back to hypoxia and reports on the prognostic significance of 
oxygen sensors in cells, namely HIF hydroxylases. We were able to access validated 
antibodies from a collaborating research group in Oxford for these biomarkers which there is 
limited data on the prognostic impact of. 
All of the investigated molecules have been proposed as potential targets in cancer and 
for some molecules there is ongoing research with directed therapies towards these targets. 
Altogether, this dissertation covers protein expression data regarding these molecules and 
their prognostic impact in NSCLC. These data will potentially improve prognostication of 
operable NSCLC patients and aid the more enduring efforts of establishing and implementing 
novel treatments for patients with this highly deadly disease. 
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2 BACKGROUND 
2.1 Lung cancer 
2.1.1 Epidemiology 
Lung cancer is by far the number one killer among cancers in the western world, 
independent of gender, and in the US it accounts for more cancer related deaths than prostate, 
colorectal and breast cancer combined.(2;3) In Norway, there was diagnosed 1519 and 1129 
new cases in men and women in 2009, almost 6 persons die every day of lung cancer and  
nearly 20% of all cancer related deaths were due to lung cancer.(1) In the US, lung cancer 
mortality has already dropped sharply for men and has reached its peaking threshold for 
women, whereas in Norway the peaking threshold for men has just been reached and there is 
still a solid increase for women (Figure1).  
 
 
Figure 1: Trends in incidence and mortality rates and 5-year relative survival proportions 
(adapted from www.kreftregisteret.no; cancer in Norway 2008.) 
 
As to the causes of lung cancer, cigarette smoking is by far the most important 
etiologic factor due to the high content of carcinogens in cigarette smoke and tobacco 
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products is generally by far the largest voluntarily source of human exposure to 
carcinogens.(4) Other known carcinogens for lung cancer are asbestos, radon, arsenic, 
cadmium and chromates.(5) Never smokers account for up to 25% of lung cancer patients and 
has recently been suggested as a separate entity due to differences in epidemiological, clinical 
and molecular characteristics.(6) The incidence patterns of lung cancer are highly linked to 
smoking habits in the population. Never smoking men have been estimated to have a risk of 
0,2% to develop lung cancer, whereas current smokers was estimated to have a risk of 15,9% 
% to develop lung cancer by 75 years of age in the UK.(7) In Norway we have had a steady 
decline in daily smokers (Figure 2), but the decline started later than in the, probably 
explaining the different trend in incidence patterns between Norway and US. Regarding 
survival of lung cancer in Norway there seems to be a recent promising, but minor increase in 
the otherwise depressing 5-years survival (Figure 1). 
 
Figure 2: Female and male daily smokers and occasional smokers in Norway 16-74 year-




Morphologically and clinically, lung cancer is usually divided in two main entities: 
Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the 
largest group (80% of lung cancers) and the major morphologic subtypes are adenocarcinoma 
(AC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC).(8) Internationally and 
nationally there has been a shift from squamous cell carcinomas to adenocarcinomas as the 
most frequent NSCLC subtype, probably due to increasing sales of filter cigarettes. 
Adenocarcinoma is also the commonest subtype among never-smokers. 
Traditionally there has been little treatment-related interest in histological subgroups 
of NSCLC. However, this stand is challenged by the implementation of novel therapies where 
efficacy and side effects is highly dependent on histological subgroups.(9;10) Pemetrexed 
(Alimta®), which is a new multitargeted antifolate agent, has shown efficacy in 
adenocarcinoma and large-cell carcinoma, but not in squamous cell carcinoma.(11) The 
vascular endothelial growth factor (VEGF) antibody bevacizumab (Avastin®) have a modest 
efficacy in non-squamous NSCLC, but the drugs` efficacy was not tested in squamous cell 
histology due to initial reports on serious adverse events (hemoptysis) in patients primarily 
with squamous cell histology.(12)  The efficacy of intracellular tyrosine kinase inhibitors of 
epidermal growth factor (EGFR) like erlotinib and gefitinib is also mainly found in 
adenocarcinoma. In our studies, bronchioalveolar carcinoma (BAC) has been mentioned as a 
subtype of adenocarcinoma due to its different prognostic significance. Other sub typing has 
not been elaborately covered in this report as there is no known prognostic or predictive 
impact of other histology subtypes.  
2.1.3 Diagnosis and staging (TNM) and prognosis 
There are currently no generally implemented screening programs for lung cancer. 
Recently, the first results from the randomized NCI-sponsored National Lung Screening Trial 
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(NLST) were published in NEJM.(13) US citizens between 55-74 years of age with a history 
of heavy smoking were randomly assigned to a yearly low-dose CT or regular chest 
radiography. Although the results are premature and there is a concern of overdiagnosis, there 
was significantly reduced lung cancer mortality in the CT screened population. 
Since early lung cancers often are asymptomatic, the debuts of symptoms often 
indicate advanced disease. Today, a lung tumor is either an incidental finding on a chest x-
ray/CT or a finding after dedicated investigation. The goal of the diagnostic procedures is to 
establish a sufficient evidence of the disease (histology) and clinical stage. A chest CT 
including the upper abdomen is usually required for a proper identification of a lung tumor 
and ruling out regional metastases in the chest as well as distant metastases in the liver and 
suprarenal glands. To establish a diagnosis, sampling of tumor tissue through tissue biopsy 
and/or brush cytology is usually obtained by bronchoscopy. However, peripheral tumors often 
require CT guided biopsy. After a confirmed diagnosis of NSCLC, further staging procedures 
are necessary to establish the extent of disease burden. Brain MRI and a bone scan are often 
done to rule out apparent brain and bone metastasis. PET scans are helpful and are 
increasingly becoming available to evaluate if there is mediastinal or distant metastasis and to 
define the tumor volume for treatment planning in radiotherapy. (14) Patients also undergo 
lung function tests to determine operability. 
An updated TNM Classification of Malignant Tumors was published in 2009 and 
included a new classification for lung cancer.(15) The revised classification was a product of 
the International Association for the Study of Lung Cancer (IASLC) staging project (Figure 
2).  A correct TNM stage is pivotal to secure appropriate and correct therapy for the patients. 
For patients that are candidates for curative surgery, it estimates the postoperative survival 
and thereby guides the use of adjuvant therapy. 
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Table 2: The seventh edition of TNM classifications and stage groupings (adapted from ref 15) 
Stage Sub-
stage 




 Tx Primary tumor not assessed or 
proven only by cells 
N0 No regional lymph node metastasis M0 (no distant metastasis)  
Stage 0  Tis carcinoma in situ N0 M0  
T1a Tumor ≤ 2 cm M0 IA 
T1b Tumor ≤ 3 cm >2 cm 
N0 
 
73% Stage I 
IB T2a Tumor ≤ 5cm > 3 cm N0 M0 58% 
T1a N1 metastasis in ipsilateral hilar LN M0 
T1b N1  
T2a N1  
IIA 
T2b Tumor ≤ 7 cm > 5 cm N0  
46% 
T2b N1 M0 
Stage  II 
IIB 
T3 Tumor > 7 cm/invading chest 
wall, pleura or pericardium/in the 
main bronchus <2 cm from carina 
N0  
36% 
T1 N2 metastasis in ipsilateral mediastinal 
and/or subcarinal lymph nodes 
M0 
T2 N2  
T3 N1  
T3 N2  
T4 Tumor invading mediastinum, 
heart, great vessels, trachea, 
esophagus, vertebral body, carina or 
tumor in another ipsilateral lobe 
N0  
IIIA 
T4 N1  
24% 
T4 N2 M0 
Stage III 
IIIB 
Any T N3 metastasis in contralateral mediastinal, 
hilar, scalene or supraclavicular LN 
 
9% 
Stage IV IV Any T Any N M1A pleural or pericardial 
effusion or separate tumor in 
contralateral lobe 
M1B distant metastasis 
13% 
T, N and M subclassification description appears only once
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2.1.4 Treatment of NSCLC 
Surgery, chemotherapy and radiotherapy are the main pillars of NSCLC treatment. 
However, there is a current trend in lung cancer towards personalized treatment based on 
clinical factors, but more importantly on factors relating to the tumor tissue (“tissue is the 
issue”). 
2.1.4.1 Curable NSCLC 
NSCLC is potentially curable with a > 50% chance of 5-year survival if no nodal 
metastases are present and the tumor is ≤ 5 cm (see Table 2 for survival details). Surgical 
resection is the treatment of choice in potentially curable patients, stage I-IIIA. Subsequent 
adjuvant chemotherapy has been introduced in NSCLC for stages IIA-IIIA. The patients in 
our studies were, however, treated prior to the introduction of adjuvant chemotherapy in 
NSCLC 2005.(16) Today, approximately 50 % have distant metastasis at presentation and a 
large number of diagnosed patients are inoperable due to comorbidity. This leads to the low 
overall resection rate of 20% recorded in Norway in 2008 with a promising increase recent 
years(17;18). Reduced lung function or serious heart conditions can lead to more marginal 
resections than otherwise wanted or even no surgery. A wedge resection is generally 
considered an inferior surgery for NSCLC, although a small non-randomized study has shown 
comparable results with standard lobectomy/bilobectomy or pulmonectomy.(19) 
Postoperative radiotherapy in NSCLC should be given to patients with N2 disease 
and/or non-radical resection margins as these patients may have a survival benefit.(20;21) If 
patients present with locally advanced disease without poor prognostic factors (tumor size >8 
cm, poor performance status and >10% weight loss last six months), they may be offered 
chemoradiotherapy. Medically inoperable patients may also be candidates for localized 
radiotherapy (60-70Gy) with or without chemotherapy.(22) 
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Today, there is no routine use of molecular targeted drugs in curative treatment of 
NSCLC. But there are a large number of trials of targeted drugs in adjuvant and even 
neoadjuvant setting for subgroups of NSCLC patients. Including vaccine studies, there are 
currently >30 studies with targeted drugs in clinical trials. (www.clinicaltrials.gov; accessed 
15.02.11) 
2.1.4.2 Advanced NSCLC 
Advanced NSCLC, which constitutes the vast majority of patients, are treated with the 
aim of life prolongation and palliation. The benefit of chemotherapy in advanced NSCLC was 
debated as late as 1995 (23), but today a “platinum doublet” including platinum is considered 
standard and provides a survival benefit with a expected survival of 6-14 months. Overall 
quality-of-life (QOL) is also improved with chemotherapy, with improvements in disease-
specific symptoms. (24) Furthermore,  radiotherapy is an effective option, especially in 
reducing distressing symptoms like hemoptysis, cough, dyspnea and pain.(25) 
Recently, molecular targeted therapies have been introduced in advanced NSCLC. 
Adding bevacizumab to standard first-line chemotherapy has improved response rates, but 
with minimal improvements in survival rates.(12) Drugs targeting the EGFR pathway have 
been studied in several NSCLC phase III trials. Monoclonal antibodies against EGFR, in the 
form of cetuximab, has been shown to marginally improve survival when added to 
chemotherapy in patients expressing EGFR (26), but has not been approved by the US Food 
and Drug Administration (FDA) or European medicines agencies. The small molecular 
tyrosine kinase inhibitors (TKI) of EGFR, erlotinib and gefitinib, have response rates of 
approximately 10% in an unselected population. Erlotinib has been approved by the 
regulatory authorities due to improved overall survival in second-line, whereas gefitinib has 
been approved only in patients with activating somatic mutations in the EGFR gene. 
Improved TKI efficacy has been shown in the following subgroups: Females, never smokers, 
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adenocarcinomas and East Asian ethnicity, most possibly representing a higher prevalence of 
activating somatic mutations in these groups, predicting response to EGFR therapy.(27) 
Guidelines depicting testing details for activating somatic mutations, interpretation and 
consequences of such testing are currently being developed in Norway and European 
consensus has also recently been met.(28) 
2.2 Hypoxia and angiogenesis 
2.2.1 Hypoxia 
Oxygen is a vital part of human metabolism as the presence of oxygen enables the 
cells to retrieve around 16 times more energy out of glucose than what is otherwise possible 
under anaerobic conditions. In growing tissue, as in tumors or during development, there is a 
changing oxygen pressure in which these cells have to adapt to survive and proliferate. 
Ambient air contains 21% O2 (150 mm Hg). Most tissues are at 2-9% O2, with tissue hypoxia 
usually defined at ≤2%. In lung tumors, median tumor oxygen tension has been measured at 
2.2% (range 0.1-6%), indicating hypoxia to be a prevalent feature.(29). Based on histological 
studies of lung tumors, Thomlinson and Gray in 1955 proposed that the necrosis, found in 
cores surrounded by viable cells neighboring a capillary vessel, was due to hypoxia. (30) 
Later, hypoxia could be measured more precisely by electrodes, but there has been found a 
considerable inter- and intra-tumoral variability demanding more precise and dynamic scoring 
of hypoxia.(31;32) Additionally, this is probably even more complicated as hypoxia is not 
only a chronic feature, but can also be acute due to changing dynamics of blood flow. 
Furthermore, cancer cells with one type of hypoxia may have a different treatment response 
than cells with the other type.(33;34) 
Hypoxia is a cardinal phenotype of the tumor environment, both due to tumor 
respiration and due to neoplastic cell colonization of tissues without a prerequisite blood 
supply. The low oxygen tension trigger the gene expression towards a more aggressive 
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phenotype and hypoxia reduces the sensitivity to therapy. These characteristics are the result 
of activation of key hallmarks of cancer like angiogenesis, metastasis, increased DNA 
replication and proliferation in both hypoxia induced factor (HIF) dependent and independent 
manners (see HIF section for details). The observation by Schwarz et al. that hypoxic cells are 
less sensitive to radiotherapy, is more than 100 years old.(35) Almost 50 years later Gray and 
others managed to establish evidence for the radioresistance seen in hypoxia in vitro.(30;36) 
In a following murine study, Powers and colleagues found decreased tumor cell survival in 
irradiated lymphosarcomas from mice breathing hyperbaric O2, and Churchill-Davidson found 
evidence for the same phenomenon in cancer patients.(37;38) Although hypoxia is recognized 
as a key feature of resistance to radiotherapy, the later hypoxia-modifying studies with 
hyperbaric O2 and hypoxic cell radiosensitizers, have in general been disappointing, thus 
hypoxic modification is normally not influencing clinical practice.(39) Hypoxia is also known 
to mediate resistance to chemotherapy, both directly and through the often simultaneously 
raised interstitial fluid pressure (IFP) (40;41) 
Figure 3: Tumor cells and gradients of oxygen.  
  
With a decreasing oxygen tension there is increased HIF1α activity, increased production of acid, increased rate 
of glycolysis and an increased resistance to chemo and radiotherapyFigure copied from ref (40). Permission 
obtaind from Springer© 
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2.2.2 Angiogenesis 
Sustained angiogenesis was included as a hallmark of cancer in a renowned review by 
Hanahan and Weinberg.(42) Angiogenesis is the physiological phenomenon of growth of new 
vessels from pre-existing vessels as opposed to vasculogenesis where blood vessels are 
formed without pre-existing ones.(43) Oxygen and nutrients are brought to the tissues by 
diffusion and blood supply. Thomlinson and Gray measured the band of live cancer cells 
surrounding a vessel to be about 170 µm wide which is close to the calculated distance of O2 
diffusion 140 µm. If tumor cells are to survive and proliferate further away from vessels, new 
vessels will have to be made.(30) Folkman stated in 1971 that angiogenesis was crucial if 
tumors were to grow beyond 1-2 mm
3
 and proposed the idea of targeting angiogenesis.(44) 
Angiogenesis is a complex and dynamic process. In physiological angiogenesis several 
factors are involved in a tightly regulated manner. Tumor angiogenesis is more chaotic, but 
orchestrated by the same factors.(45) 
Some of the most important factors are growth factor families like vascular endothelial 
growth factor (VEGF), placental growth factor (PLGF), platelet derived growth factor 
(PDGF), fibroblast growth factor (FGF) and their receptors, as well as players in other 
pathways like the angiopoietins (Ang) and their Tie-2 receptor, NOTCH-Deltalike ligand 4 
(DLL4) and endogenous angiogenesis inhibitors like vasohibin, angiostatin, endostatin, 
trombospondin-1 and tumstatin.(46) 
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Figure 4: Angiogenesis with emphasis on angiopoietins.  
a) A small focus of tumor cells served by diffusion. Angiogenesis not needed and pericytes stimulate endothelial 
cells (ECs) with Ang-1 to maintain vessel integrity and barrier function of ECs. b) Ang-2 mediates pericyte 
dissociation, increased permeability and sensitizes the ECs to growth factors, especially VEGF-A. c) Vessel 
sprouting is driven the migration of delta-like4 (DLL4) expressing tip endothelial cells following a VEGF-A 
concentration gradient. The proliferation of NOTCH1 expressing stalk ECs mediated by VEGF-A are elongating 
the sprout. These ECs are subsequently stimulated by Ang-1 secreting pericytes recruited partly by Ang-1 and 
PDGFB facilitating a robust vasculature. Epidermal growth factor-like domain multiple 7 (EGFL7) regulates 
lumen formation. d) A growing and vascularized tumor mass showing some of the possible therapeutic 
intervention points. As published in (47). Permission obtained from Nature Publishing Group©. 
 
2.2.3 Biomarkers associated with hypoxia and angiogenesis 
covered in this thesis 
2.2.3.1 Hypoxia induced factors (HIFs) 
In 1992 Semenza and Wang recognized and purified the hypoxia inducible factor 
(HIF) as the promiscuous transcription factor at the heart of cell adaptation to shifting oxygen 
tension(48). HIF is the active heterodimer of HIFα and HIFβ. HIFα is one of the proteins with 
the shortest known half-life, but also detectable less than 2 minutes after exposure to 
 21 
hypoxia.(49) The quick response of shifting oxygen tension facilitates rapid regulation of its 
gene targets. Stabilized HIFα will bind to the constitutive HIFβ-subunit and translocate to the 
nucleus. In the nucleus it will exert its action as a transcription factor, by binding to hypoxia 
responsive elements (HRE) in the promoter regions of target genes (Figure 5). 
Among the three HIFα-subunits (HIF1α, HIF2α and HIF3α), HIF1α was the first HIF 
family member to be described and the most studied. HIF1α is ubiquitously expressed and 
induces a wide range of hypoxia-inducible genes. It is highly expressed in many different 
tumors, but infrequent in most normal tissues.(50;51) Over expression of HIF1α has 
consistently been found associated with a poor prognosis in a broad range of tumors 
(reviewed in ref (52)), also in NSCLC.(53) Also the HIF2α isoform seems important in 
physiology as targeted disruption of HIF2α leads to embryonic lethality. Although HIF1α and 
HIF2α share significant sequence homology, they have unique tissue distributions and effect 
on tumor progression. Whereas HIF1α is found almost in every tissue, HIF2α expression is 
more restricted and seems to be highly expressed in tissues mainly involved in systemic 
delivery of O2, like lung, heart and endothelium. Regarding target genes, HIF1α uniquely 
stimulates the expression of many enzymes like lactate dehydrogenase 5 (LDH5) and 
carbonic anhydrase IX (CAIX), while transforming growth factor-α (TGF-α) and 
erythropoietin (EPO) are upregulated in hypoxia by HIF2α. Other transcriptional genes like 
glucose transporter 1 (GLUT1) and VEGF-A are commonly upregulated by both 
subunits.(reviewed in ref (54)) The contribution by HIF3α is not yet properly determined, but 
it is rapidly induced by hypoxia in most tissues, and a splicing variant appears to be an 
antagonist of the HIF system.(55;56) 
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Figure 5: Schematic function of hypoxia-inducuble factor-1α.  
In hypoxia HIF1α will be stabilized, translocated to the nucleus, dimerize with HIF1β, bind to a hypoxia 
responsive element (HRE) and lead to hypoxia-responsive gene activation. Under normoxia HIF1α will by 
hydroxylated by prolyl hydroxylases (PHDs) leading to von-hippel-Lindau (VHL) binding and ubiquitin 
mediated proteasomal degradation. As published in (57).Permission obtained from AACR© 
 
 
Figure 6: The Hypoxia induced factors (HIFs)-subunits.  
The three HIFα subunits share structural similarities. The basic helix-loop-helix (bHLH) mediates DNA binding 
and the PER-ARNT-SIM (PAS) domain mediates dimerization of HIFα and HIFβ subunits.  The potency of 
HIFs is related to the transactivation domains (TADs). An oxygen-dependent degradation domain (ODD) is the 
area in which hydroxylation due to prolyl hydroxylases occur, leading to proteasomal degradation.  ARNT -1 
and -2 are the isoforms of the HIFβ-subunit. As published in (52).Permission obtained from nature publishing 
group.© 
 23 
2.2.3.2 HIF induced gene products  
More than 100 well-defined gene products are induced by HIF.(58) These molecules can 
be grouped into several characteristic cancer cell qualities like altered:(59) 
• Metabolism; GLUT1, hexokinase 1 and 2, LDH5 
• Oxygen sensing; Prolyl hydroxylase (PHD) 2 and 3  
• pH homeostasis; CAIX and CAXII 
• Angiogenesis; VEGF-A, PLGF, PDGFB, Ang-2 
• Erytropoiesis; Erythropoietin (EPO) 
• Metastasis; Chemokine receptor type 4 (CXCR4), lysyl oxidase 
• Invasion; Endothelin 1, fibronectin 1, matrix metalloproteinase (MMP) 2, 14 and C-
met 
• Genomic instability; Differentiated embryo-chondrocyte expressed gene 1 (DEC1) 
• Cell survival /immortalization and autophagy; Survivin, telomerase and 
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (Bnip3) 
• Epithelial-mesenchymal transition (EMT); TWIST1, Zinc finger E-box-binding 
homeobox (ZEB) 1 and 2 
In the following I will focus on GLUT1, CAIX and LDH5 since these are part of my 
IHC-studies. GLUT1 and CAIX were included due to their proposed, but controversial 
role as endogenous markers of hypoxia (60-62), and LDH5 because it is one of the most 
known HIF-induced molecules and involved in metabolism like GLUT1. Angiopoietins 
and prolyl hydroxylases are reviewed in other sections. 
2.2.3.2.1 GLUT1 
Sugars are an important substrate for energy production through cellular respiration with 
oxidative phosphorylation as the final and most productive step. However, cancer cells mainly 
utilize glycolysis as discovered  by Warburg more than 50 years ago.(63) In fact, cancer cells 
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actually prefer glycolysis with or without the presence of oxygen. To achieve this phenotype, 
an increased import of sugars, mainly glucose, is needed. Other sugars like fructose can be 
used, but glucose uptake is the rate-limiting step. Sugars are hydrophilic and need to be 
transported into cells by glucose transporters. Transportation is mediated through membranes 
by membrane proteins such as facilitated glucose transporters (GLUTs) or sodium/glucose co-
transporters (SGLT). There are several subtypes of these sugar transporters, but GLUT1 is 
responsible for the basal glucose uptake which is probably why it is the most studied glucose 
transporter in cancer. It is also related to the rate of glucose metabolism and it is expressed in 
all tissues. GLUT1 is induced by hypoxia (reviewed in ref (64)), but it is also known to be 
regulated by c-Myc.(65) 
2.2.3.2.2 CAIX 
Cellular biochemistry can be significantly altered by small changes in pH and proper 
regulation is vital for survival and function of cells. Cancer cells are characterized by a high 
metabolism and therefore must be able to handle the high intracellular production of excess 
protons (H
+
) by transporting these from the inside of the cells to the extracellular 






-lactate co-transport or HCO3
-
 
(bicarbonate) dependent buffering with a subsequent extracellular CO2 diffusion. For the 
bicarbonate-dependent buffering to be efficient, catalysis by carbonic anhydrases is 
imperative. In cancer, the extracellular bound carbonic anhydrase IX (CAIX) has been of 
increasing interest due to its induction by hypoxia, and that its expression has been found in 
many cancers, but rarely in normal tissues. Expression of CAIX is related to hypoxia below 
1% O2 and is therefore seen expressed between 80-130 µm from blood vessels (reviewed in 
ref (66)). Among the molecules related to hypoxia, CAIX has by some been proposed as one 




Due to the high metabolic rate of cancer cells by glycolysis and the use of citric acid 
(TCA) intermediates for cancer cell membrane composition, there is a high production of 
pyruvate not needed for further energy production. Hence, pyruvate is converted to lactate by 
lactate dehydrogenases. Among five isoenzymes, lactate dehydrogenase 5 (LDH5), also called 
LDHA, has the highest efficiency in catalyzing pyruvate to lactate. Lactate can subsequently 
be transported to the extracellular space by a monocarboxylate transporter. LDH5 is also 
induced by HIF1α and is overexpressed in common cancers like NSCLC(67;68) head and 
neck cancers(69), non-Hodgkin B-cell lymphomas (70) and colorectal cancers (71). 
 
 
Figure 7: Examples of proteins grouped into several characteristic cancer cell qualities expressed as a result of 
a HIF-mediated hypoxia-response. As published in ref (40). Permission obtained from Springer© 
2.2.3.3 Angiopoietins 
Angiopoietin (Ang)/Tie-2 receptor signaling plays a critical role in concert with 
VEGF-A in angiogenesis.(72;73) This axis has proved crucial as withdrawal of VEGF-A 
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causes endothelial cells (ECs) lacking support of pericytes to undergo rapid apoptosis, while 
ECs, with supporting mural cells expressing Angs, survive.(72;74-76)  
There are three known human ligands for the tyrosine kinase Tie-2, namely Ang-1, 
Ang-2 and Ang-4. Ang-1 stimulates the kinase activity of Tie-2 upon binding. Ang-2 has been 
shown to act as a context-dependent antagonist or agonist for Tie-2 with the antagonism as the 
best described effect.(77;78) Ang-4 is a ligand which seems to have the same agonistic effect 
on Tie-2 as Ang-1, but is less studied.(79;80) Tie-2 downstream signaling most importantly 
mediates cell survival which in the vascular compartment maintains vascular quiescence, but 
also exerts anti-inflammatory effects. There is also another tyrosine kinase receptor, Tie-1, 
which has no known ligands, but binds to Tie-2 and regulate its activity.(81) Although its 
function regarding angiogenesis has been mostly studied in ECs and pericytes, there are also 
accumulating evidence that expression of Ang-2 in tumor cells is involved in cancer 
progression and metastasis in glioma (82-84), gastric cancer (85), colorectal cancer (86;87), 
prostate cancer (88) and breast cancer (89).  
2.2.3.4 HIF hydroxylases 
Regulation of the HIF activity is mainly controlled by the half-life of the HIFα-
subunit, which is tightly controlled by the oxygen dependent post-translational hydroxylation 
by HIF hydroxylases. Under normoxia, HIFα is hydroxylated by prolyl hydroxylases (PHD1, 
PHD2 and PHD3) and factor inhibiting HIF (FIH). Hydroxylation of the proline residues in 
the N-terminal area transactivation domain (N-TAD) by PHDs enables binding with von 
Hippel-Lindau (VHL) tumor suppression protein with subsequent targeting of HIFα for 
proteosomal degradation by polyubiquitation.(90;91) The different PHDs share a 42-59% 
sequence similarity. Principally all PHDs have the same function, but appear to have different 
specificities for various hydroxylation sites.(92) PHD2 is the most abundant form and it is the 
main regulator of HIF1α activity, probably due to its relative abundance. RNA interference 
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against PHD2 induces stabilized HIF1α subunits whereas PHD1 and PHD3 silencing had no 
effect on HIF1α –stabilization. PHD3, on the other hand, more efficiently regulates 
HIF2α.(92;93)  
FIH hydroxylates the C-terminal transactivation domain (C-TAD) of HIFα. This 
prevents transcriptional activation due to the inhibitory effect of this hydroxylation on the 
interaction between HIF and coactivators like p300.  
Together, these hydroxylases are known as HIF hydroxylases and serve the function of 
oxygen sensing in the vital cellular oxygen homeostasis.(94;95) PHD expression has been 
detected in most normal human tissues, but in malignancy PHDs are overexpressed in 
common cancers like breast, prostate and head and neck whereas a slight decreased 
expression compared to normal tissue was suggested in lung cancer, renal cell carcinomas and 




Figure 8:HIF hydroxylases and their regulated genes under various oxygen tension  
 
HIF1α has two transactivation domains (TADs); a N-terminal domain (N-TAD) and a C-terminal domain (C-
TAD). With decreasing O2-tensions the hydroxylation by the HIF-hydroxylases (PHDs and FIH) are decreased, 
inducing stabilized HIF1α with transcriptional activity. However, PHDs require higher oxygen tension than FIH 
for hydroxylation. This enables a two-step regulation of HIF1α. At moderate hypoxia, PHD function is 
terminated resulting in stabilized HIF1α which can transcribe N-TAD genes, but transcription of C-TAD genes is 
still blocked by the hydroxylation of FIH. In severe hypoxia, both FIH and PHDs are inactive enabling 
transcription of both N-TAD and C-TAD genes. As published in ref (57). Permission obtained from AACR© 
 
2.3 Predictive or prognostic biomarkers  
A biomarker is defined according to the following: It must be objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes or 
pharmacological responses to a specified therapeutic intervention.(97) It must also harbor 
properties valuable in the clinical setting, either as a prognostic or predictive marker. 
A prognostic marker is a factor showing a statistically significant association between 
its presence and outcome. A clinical useful prognostic marker must also be statistically 
independent, easy to determine and interpret and have therapeutic consequences. Prognostic 
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biomarkers for progression, relapse and survival are important for patient handling and 
treatment, and especially in the patient selection for adjuvant treatment strategies. 
A predictive marker is a factor showing a statistically significant association with the 
benefit from being assigned to a specific therapy. A biomarker with predictive value gives 
information on the effect of a therapeutic intervention in a patient. It is therefore helpful in 
identifying subgroups of patients with differential responses across therapies.(98) 
2.4 Implemented biomarkers and clinical outcome in NSCLC 
Molecular marker research has exploded during the last decade, also in NSCLC. But 
few have, hitherto, adopted into current clinical practice. Molecular markers must harbor 
properties that are valuable in the clinical setting, either as prognostic or predictive markers. 
These have been reviewed in ref (99-101). 
 
Epidermal growth factor receptor (EGFR) mutations: EGFR (also named HER1) is 
one of four epidermal growth factors. As more than 60% of NSCLC patients express EGFR, 
EGFR has become an important therapeutic target for treatment in NSCLC. Initial subgroup 
analyses identified clinicopathological factors like Asian ethnicity, female sex, 
adenocarcinoma histology and light/never smokers to predict response to EGFR TKIs. 
However, we are now aware that these factors select for a population with sensitizing 
mutations within the TKI domain, which 10-15% of patients have. Around 85-90% of known 
EGFR activating mutations are either exon 19 microdeletions or exon 21 point mutations. 
(102;103) Recently, promising, but premature results from the EURTAC were presented at 
ASCO 2011 showing 55% response rate to erlotinib for patients with activating mutations vs 
11% for patients with activating mutations randomized to chemotherapy.(104) In a up-to-date 
review Ellis et al. conclude that diagnostic lung cancer samples of patients with advanced 
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NSCLC of non-squamous histology should be routinely tested for activating mutations in the 
first-line setting. 
 
Echinoderm microtubule-associated protein-like 4 (EML4) and the anaplastic 
lymphoma kinase (ALK) fusion (EML4-ALK):  A translocation of these genes results in a 
fusion protein resulting in a distinct entity of NSCLC. There is no specific therapy approved 
for ALK-associated NSCLC, but as targeted agents are emerging I have included this 
biomarker although not implemented yet. The EML4-ALK translocation is found in as few as 
1-7% of NSCLC patients. This translocation seems to serve as a predictive marker for ALK 
inhibitor therapy. These translocations and EGFR mutations are mutually exclusive. 
(101;105) 
No prognostic molecular biomarkers have been generally implemented although 
several have been suggested. 
2.5 Microenvironment - tumor vs stroma 
Although the “seed and soil” hypothesis was presented more than a century ago by 
Stephen Paget we are now starting to comprehend the complex crosstalk between the tumor 
cells (the “seeds”) and the tumor-growing microenvironment (the “soil”). Tumors are 
complex tissues composed of malignant neoplastic cells as well as a tumor stroma with 
various non-malignant cells and extracellular matrix (ECM). Stromal properties can be 
defensive, permissive or even cooperative towards malignant cells to facilitate growth, 
invasion and metastasis. The malignant tumor has been compared to a new organ within the 
tissues as malignant cells are able to recruit and exploit the microenvironment to produce a 
supportive microenvironment for the neoplastic cells.(106-109)   
The ECM contributes to the stroma with structural proteins (collagen, elastin), 
specialized proteins (fibrilin, fibronectin, elastin) and proteoglycans. NSCLC tumors are also 
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a heterogeneous mixture of cells. The main cells in a NSCLC tumor are the neoplastic cells, 
mesenchymal supporting cells like fibroblasts and adipocytes as well as vascular cells and 
immune cells. I will here present fibroblasts and immune cells.  
2.5.1 Carcinoma associated fibroblasts 
 Fibroblasts are activated by tissue injury with the function of depositing and turning 
over ECM. In tumors, activated fibroblasts constitute a major portion of the reactive tumor 
stroma and play a crucial role in tumor progression. Due to the acknowledgement of their 
supportive role in tumor progression they have been entitled carcinoma-associated fibroblasts 
(CAFs). They have, however, been hard to identify due to a lack of a cell-specific marker and 
are defined for the most part of what they are not, non-smooth muscle cells, non-endothelial 
cells and non-epithelial cells. However, during activation many of them express smooth 
muscle actin and these are referred to as myofibroblasts or activated fibroblasts. By secretion 
of growth factors, ECM-degrading proteases, involvement in endothelial-mesenchymal 
transition (EMT) by e.g. TGFβ they are involved in cancer promoting features like growth, 
migration and invasion. Their role in cancer have been extensively reviewed (107;110), and 
the role in NSCLC has recently been reviewed by our research group.(111) 
2.5.2 Immune cells 
The immune system in cancer has also been described to be involved in both cancer-
protective and cancer-promoting features. However, in already established malignancies, 
there is accumulating evidence for the role of the immune systems in tumor progression, 
invasion, metastasis and avoidance of an effective immune response.(112-114) The immune 
system can be separated in two distinct systems: The innate and adaptive immune system. 
The innate immune system involves cells as dendritic cells (DCs), natural killer (NK) 
cells, macrophages, mast cells and granulocytes. These are our first defense line against 
foreign pathogens and they are able to react rapidly to tissue injury. Normally, an innate 
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immune response is temporary and tissue homeostasis is restored thereafter. However, in 
cancer there is chronic inflammation and several subsets of the innate immune system have 
been shown to exert tumor promoting effects. For instance, tumor-associated macrophages 
(TAMs) are mostly activated through the M2 pathway known to promote invasion, 
angiogenesis, metastasis and immunosuppression in carcinomas and when found in tumors, 
they have consistently been associated with a poor prognosis.(112-114) 
The cells in the adaptive immune system are B-lymphocytes which are mainly antibody 
producing cells and T-lymphocytes of CD4+ (helper) or CD8+ (cytotoxic) subtypes. These 
cells are specialized by a slower, but a sophisticated and effective antigen-specific response. 
In cancer, the role of the adaptive immune cells is debated. In favor of tumor-promotion are 
the classic regulatory T cells which are CD4+CD25+FOXP3+. These cells suppress the 
otherwise effective anti-tumor responses of cytotoxic T-cells. Depending on the etiology of 





3 AIMS OF THESIS 
Based on existing knowledge about angiogenesis, hypoxia and stroma described in 
chapter 2, the general aim of this study is to study known biomarkers involved in 
angiogenesis and hypoxia with regards to their relevance in NSCLC progression. 
More specifically the aims of this thesis are to: 
1. Examine immunohistochemical expression of important molecules in 
angiogenesis and cell adaptation to hypoxia in NSCLC 
2. Examine the prognostic impact of these biomarkers for disease-specific survival 
alone and adjusted for known prognostic factors 
3. Help establish candidate markers for better prognostication for NSCLC patients 
4. Suggest possible targets for therapy 
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4 MATERIALS AND METHODS 
4.1 Patients 
Patients with pathological stage I to IIIA NSCLC were identified through the 
pathological departments at the University Hospital of Northern Norway (UNN) in Tromso 
and the Nordland Central Hospital in Bodo. Among the 371 identified patients, 36 were 
excluded from the study due to: Radiotherapy or chemotherapy prior to surgery, other 
malignancy within five years prior to NSCLC diagnosis, or inadequate paraffin-embedded 
tissue blocks (Figure 9). Patient characteristics are presented in Table 6, section 5.1. 
 
Figure 9: Patient inclusion and exclusion 










Other malignancy within five 
years prior to NSCLC diagnosis.
N = 13
335 patients with complete  
medical records and adequate 
paraffin-embedded tissue blocks.  
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4.2  Tissue Micro Array 
Tissue microarrays have revolutionized molecular profiling in cancer as it has enabled 
high-throughput analysis. The first published report which can be associated to TMAs was by 
Battifora et al. who in 1986 described the multitumor “sausage” tissue block.(115) However, 
the first study describing a modern technology of tissue micro array (TMA) was by Wan et al. 
in 1987(116), although the casing for the cores were cut from ordinary drinking straws! Ten 
years later Kononen et al. (117) published on the development a device for rapid production 
with high quality and is referred to as the first modern TMA study. 
The most common form is the one were you take a tissue core biopsy (0.6-2 mm 
diameter) from a preselected area of interest in the tissue and insert it in a predrilled paraffin 
recipient block where a grid system makes it easy to link it to the patients’ clinicopathological 
data. Immunohistochemistry is the usual assay method, but other in-situ techniques like 
fluorescent in situ hybridization (FISH) have been used. More advanced explored alternatives 
are ultrahigh density microarrays where solid samples are stacked together, (118) use of 
frozen tissues,(119) use of cells from suspension (120) and some have even used needle 
biopsies as tissue basis.(121)  
The advantages of the TMA technology are clearly demonstrated if you consider the 
alternative with many whole sections. This requires the use of different batches requiring 
quantities of reagents and thorough manual examination of each slide. TMAs save time for 
technicians and pathologists, speeds up time from data collection to publication, specimens 
are stained at the same time and conditions securing standardization, tumor scoring can be 
done reliably by non-specialists, the tissue is saved as only small amounts of each tissue is 
needed to produce the TMA, a larger number of patients can be included which increases 
quality and power of the study and lastly the TMAs can be easily shared across research 
groups making validation easier.(122) Advantages and disadvantages of TMAs are listed in 
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Table 3. In the following sections I will go through some of the processes and how we have 
addressed these to ensure quality. 
 
Table 3: Advantages and disadvantages of tissue microarray (TMA) technology. 
Advantages (+) Disadvantages (-) 
Saves time for technician and pathologist Reduced representativity for heterogeneous 
stained tissue 
Tumor scoring can be done by non-specialists Not suitable for diagnosis 
Cost saving Dependent on TMA producing skills 
Specimens are stained consistently Still dependent on the quality of patient 
cohort 
Saves tissue Still dependent on antibody quality 
Can be shared Still dependent on the quality of tissue 
Ability to assay a large number of tissues  
 
4.2.1 Tissue sample acquisition  
Under the surgical procedure, degradation of various molecules starts as soon as the 
surgeon cuts blood supply to the tumor. The time from loss of blood supply to the tissue 
arrival at the pathological department can vary leading to a difference in expression of several 
proteins. This can theoretically be countered by standardized and rigorous tissue banking 
regimens, but there is also evidence that for instance RNA degradation occurs during surgery 
and that post-surgery banking regimens can not compensate fully.  
Our tissues have been collected from routine specimens which have been exposed to 
varying time spans without blood supply before arriving at the pathological departments, and 
we have no reliable way to reproduce the accurate time factor. However, it has been stated 
that the most valuable tissue samples with long follow-up are stored in routine pathological 
archives and that standardization of tissue handling might be too demanding considering the 
modest benefit of a stringent regimen.(123) 
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4.2.2 Tissue sample preparation 
Another important factor of post-surgery tissue handling is fixation techniques. The 
techniques may have changed during the time span the patients were treated, both regarding 
reagents and pathological preparation. Since penetration time of formalin is estimated to about 
1 mm an hour,(124) tissues of different sizes will lead to varying time for actual protein cross-
linking. We have like many others used archival tissues from a considerable time span, 
permitting variations in tissue processing techniques to bias our results. But there has been no 
systematic change in tissue handling that may systematically have bias our results. All nine 
TMA-slides had the same delay between cutting and staining. This is important as this delay 
has great influence on IHC-intensity.(125) 
4.2.3 Histological examination 
To include cases in our TMA-study we screened the pathology departments’ databases 
for suitable cases. However, diagnostic criteria for the actual diagnosis and TNM 
classifications may change over time. In addition, routine specimens may be handled by 
different pathologists. To address this issue our two experienced pathologists re-examined the 
diagnosis and revised the TNM-status as well as factors like vascular infiltration and 
differentiation for all of the included patients. In addition they selected the most 
representative areas of both tumor and stroma for sampling by our experienced technician. 
4.2.4 Collection of clinical data 
The ambition of most TMA-studies in cancer is to find associations between clinical 
outcome versus biomarker(s), and/or clinicopathological variables. Outcome and clinical data 
has to be collected from archived medical journals, possibly at different geographical 
locations where the patient has received clinical follow-up. Age and gender are variables that 
can be easily collected. Other variables included in our study, like smoking status, 
performance status and weight loss, are regularly lacking in the immediate pre-surgery 
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examination, leading to missing data if not a thorough examination by individuals with 
medical experience and medical record interpretation is done. In our case, the three 
individuals responsible for collection of data were all experienced oncologists. Updates with 
regards to outcome have been done.  
The low number of private institutions (none in our region) in Norway and the low 
level of geographical migration within Norway of these patients make it easier to collect 
reliable and comprehensive follow-up data. 
Regarding clinical outcome data, several endpoints can be selected. As our follow-up 
is long and the most lung cancer patients relapse early, we were able to use disease-specific 
survival (DSS) as the primary endpoint as the numbers of events were sufficient (137 lung 
cancer deaths, 40.9% of patients). Regarding cause of death, it may be difficult to determine 
the cause exactly. Where uncertain, we have for practical reasons assigned patients to lung 
cancer death if they died with therapy resistant local or metastatic progression of disease. 
4.2.5 TMA assembly 
After review of the patient tissues, the most representative blocks were chosen. The 
most representative areas of tumor and stroma were then selected for tissue sampling with a 
0.6 diameter tissue-arraying instrument from Beecher Instruments, Silver Springs, MD. This 
thin-walled stainless steel biopsy needle mediated the sampling of cylindrical samples from 
donor blocks and the extrusion of this core into the predrilled recipient block. Two separate 
predefined tumor areas and two predefined stromal areas were sampled from each tumor. A 
total of 335 x 4 = 1340 cores were sampled and inserted into 8 recipient blocks. In addition 20 
control specimens were collected in the same way from normal lungs and inserted in an 
additional control TMA-block. For the IHC- analyses, 4 µm sections were cut with the 
Micron microtome (HM355S). 
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4.2.6 Representativity 
Heterogeneity is a known feature in tumors (genetic, cell origin, protein expression, 
etc). In our study the mean NSCLC tumor size is 44 mm in maximum diameter. If we assume 
the tumors to have a perfect spherical form they have a mean volume of 9.21 cm
3
. Our TMA 
cores have a volume of 0.00000011 cm
3
, thereby visualizing 1/84 000 000 of the tumor. We 
employed duplicate cores in our study which increases the part of tumor or stroma visualized 
to 1/42 000 000. However, these numbers and the concern of representativity need to be put 
into context. A whole tissue section would only visualize 0.00024 cm
3
, which would equal 
1/38 000 of the same tumor. Considering these numbers it is easy to see that both a TMA core 
and a whole section can be questioned with regards to representativity. The few studies 
comparing large section analysis and TMA analysis have found them to be equally relevant 
for predicting prognosis of histological grade and Ki-67 in bladder cancer, ER and PR in 
breast cancer while TMA actually was found to be superior in predicting prognosis for p53 
expression.(126;127) 
Another way to increase representativity is to increase the number of cores from each 
tumor. This also increases workload, but is more advantageous than increasing core size.(128) 
This is especially important in studies with small patient cohorts. Larger cores can be justified 
as an alternative if more normal tissues are to be evaluated since one would need larger 
diameter cores to include all of the relevant cells. In our study this would have been 
advantageous for stromal sections as larger cores could have made us able to evaluate vessels 
and vessel expression of markers in stromal tissues. 
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4.3 Immunohistochemistry (IHC) 
Immunohistochemistry (IHC) is only one way of determining the expression of a 
given biological molecule, but it is widely adopted and it is considered the gold standard for 
in-situ protein expression evaluation in tissue sections. Immunohistochemistry has the 
advantage of being relatively inexpensive, it is established in most laboratories, staining 
intensity can be evaluated with little training, it can be done on archival tissues and expression 
can be evaluated in-situ to assess cells in different compartments and of different origins. In 
addition it is the final protein available in the tissues that is responsible for the effect of the 
marker, not the mRNA. 
For the commercial antibodies the manufacturers often provide recommendations for 
IHC-protocols for their antibody and for non-commercial antibodies the scientists often 
provide a protocol or a reference. However, these protocols have to be adapted in the local 
laboratory. There is no standardized, commercially available equipment for antigen retrieval 
so although the principles are the same, a wide variety of adaptations have to be made to find 
the best set-up for antigen retrieval, incubation time of antibodies, dilutions, washing time and 
techniques. You are therefore highly reliant on experienced technicians and thorough 
evaluation of the results from different protocols before doing the actual staining of the TMA-
tissues. Often, such rigorous demands means different antibodies have to be tested and new 
batches ordered before a satisfactory result is obtained. Occasionally the test of a potential 
biomarker has to be abandoned due to unsatisfying results. In our study, evaluation of HIF3α 
expression was abandoned due to unsatisfying staining with available antibodies. 
In our lab, two very experienced technicians have done all of the IHC-experiments. 
After satisfying staining is achieved, minimal background and expected in-situ staining, the 
slides are evaluated by an experienced pathologist with regards to specificity, controlled 
against either available literature and/or positive and negative tissue controls. 
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4.3.1 Antibodies 
The antibody is the pivotal reagent common to all immunohistochemistry. During the 
last 10 years we have seen an enormous expansion in the number of available antibodies 
directed towards an expanding number of antigens. There are two principally different 
subgroups of antibodies according to clonality; polyclonal antibodies and monoclonal 
antibodies. 
Polyclonal antibodies are a heterogeneous mixture of antibodies directed against one 
antigen, but different epitopes. The antibodies have been generated by different B-cell clones 
of an animal and the antibodies have slightly different specificities and affinities to the 
antigen. Polyclonal antibodies are collected from the serum of previously immunized animals 
by injection of an antigen/immunogen. The typical animal is a rabbit.  
Monoclonal antibodies are homogenous antibodies directed against one epitope of the 
antigen by production from a single B-cell clone. To achieve this, the spleen is taken out of a 
sacrificed immunized animal and the B-lymphocytes are isolated. These cells are then fused 
with immortalized myeloma cells. These new cell lines are further cultivated to identify and 
select the best cell line clone. You can enable this new isolated cell line to produce antibodies 
either in an artificial system (bioreactor) or you can inject these cells into the peritoneal cavity 
of an animal. 
Regarding advantages and disadvantages of monoclonal or polyclonal antibodies there 
are benefits and drawbacks with both. Polyclonal antibodies are more robust in antigen 
binding due to their ability to identify several epitopes of the antigen. The tissue specimens 
can, due to tissue sample preparations, conceal the specific epitope which a monoclonal is 
directed against. Consequently, false negative IHC results with polyclonals are infrequent. 
However, specificity is a concern since the chance of cross-reactivity of these polyclonal 
antibodies is increased making a false positive result more likely. Monoclonal antibodies also 
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have a superior lot-to lot consistency since antibody production is not dependent on the life of 
the specific animal due to the immortalized cell line. Reviewed in ref (129) 
Antibody generation is understandably a costly and time-consuming task. Therefore 
most researchers purchase commercially available antibodies. Antibody selection is a critical 
step in performing a reliable IHC-study.  
The antibodies in our study were carefully selected by reviewing available literature. 
We selected antibodies which seemed to have worked well with others or by the information 
provided by the manufacturer. It was a prerequisite that the applied commercial antibodies 
had been subjected to in-house validation by the manufacturer for IHC on paraffin-embedded 
material (IHC-P). One exception was Ang-1 which was selected due to other researchers’ 
published success with this antibody (130-134) and failure to achieve satisfying quality with 
other available IHC-P tested antibodies. The antibodies provided by The Department of 
Clinical Laboratory Sciences, University of Oxford, and Cancer Research UK, Molecular 
Oncology Laboratory, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK 
had previously been tested for IHC on paraffin-embedded material.Antibodies used in the 
studies are listed in Table 4 
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Table 4: Antibodies used in the studies 
Antigen Type Manu-
facturer 
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Abcam Ab15086 1:200 Ventana overnight at 
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Abcam Ab65835 1:30 Ventana overnight at 
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Abcam Ab82884 1:50 Ventana overnight at 
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* Department of Clinical Laboratory Sciences, University of Oxford, and Cancer Research UK 
Molecular Oncology Laboratory, Institute of Molecular Medicine, John Radcliffe Hospital, 
Oxford, UK 
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4.3.2 IHC procedure  
The nine 4 µm TMA sections containing the tissue cores were deparaffinized with 
xylene and rehydrated through graded ethanol series (manual staining) before antigen retrieval 
(described in Table 5). Antigen retrieval was for the automated procedures done by the 
Ventana Benchmark, XT automated slide stainer (Ventana Medical systems, Illrich, France).  
The visible and evaluable staining requires a multistep procedure involving the primary 
antibody bound to the targeted protein, an enzyme complex and a chromogenic substrate.  
The staining was a multistep procedure, involving a primary antibody which binds to 
the target, and a detection reagent containing a secondary antibody conjugated with an 
Avidin/Biotin/enzyme complex (manual procedure), or a polymer of secondary antibodies 
conjugated with an enzyme (Ventana procedure). In the end a chromogenic substrate was 
added, yielding a brown/reddish color at the site of the enzyme (both manual and automated 
procedure). The manual detection reagent used was “ABC Elite” kit from Vector labs. The 
detection system was the Ventana XT is Ultra View DAB. After visualizing the antibody 
target, the slides were counterstained with Hematoxylin to visualize the nuclei. 
4.3.3 IHC controls 
Positive and negative controls are required in many biological experiments to ensure 
adequate experimental quality. For immunohistochemistry, various control measurements can 
be implemented. To ensure that the antibody is specific, a western blot to ensure that binding 
of a protein with expected size is done. This procedure has usually already been performed by 
renowned and stringent manufacturers, and we have trusted these. In a recent publication, 
however, it has been argued that the purchaser should validate the specific binding.(135)  
In the actual immunohistochemistry-procedures, negative and positive controls are 
used. This is principally done by including a tissue which does or does not express the 
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antigen. This tissue should be stained with the test tissue. Often the actual test tissue itself has 
a known expression with both negative and positive cells. However, if one wants to perform 
research on novel molecules which have not previously been tested in large IHC-studies, one 
has to compromise on these demands, but with increased suspicion regarding staining. 
For the actual IHC procedure, negative reagent controls by replacing the primary 
antibody with a primary antibody diluent to check that there is no staining without the 
antibody. The negative control can be more rigorous by doing an isotype control. Isotype 
control antibodies are used to estimate the non-specific binding of target primary antibodies 
due to Fc receptor binding or other protein-protein interactions. An isotype control antibody 
should have the same immunoglobulin type and be used at the same concentration as the test 
antibody. Another control, although less used, is the pre-absorption control experiment where 
excess amounts of target protein (if available) are premixed with the primary antibody before 
incubation with the tissue. As all antibodies should be pre-bound to the available antigen in 
the solution, no staining should be detected. Some recommend this control especially for 
polyclonal antibodies as some clones may be non-specific.(136) 
The positive IHC controls are to ensure that tissue supposed to be stained is actually 
stained. This is mostly done by including human tissue in the IHC-procedure which is 
consistently known be positively stained. Some have even constructed TMAs of various cell 
lines with known expression levels for validation. Some of these cell lines can even be 
formalin fixed cells transfected with the target protein. The tissue itself can also be the 
positive control if previous staining patterns for the tissue are known. By including stroma in 
the TMA studies a lot of non-neoplastic cells are included for which an expression profile is 
usually established. This aids validation of staining as we can control our staining against 
established expression profiles. 
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In our experiments we have used the following controls: 
 
Paper 1: Negative controls were simultaneously performed for all antibodies by omitting the 
primary antibody. No formal positive controls as the target proteins had well known 
expression in NSCLC 
Paper 2: Negative controls were simultaneously done for all antibodies by omitting the 
primary antibody, and an appropriate isotype control was done for all antibodies on one of the 
TMA slides. Capillary vessels in stromal cores with high expression were used for internal 
positive controls and skin hemangiomas as external positive controls. 
Paper 3: Negative controls were simultaneously performed for all antibodies by omitting the 
primary antibody. For the commercial antibody for PHD1 we used normal testis as a positive 
control. For the donated antibodies, staining patterns in tumor and normal lung were 
compared to what has been published earlier regarding staining with these antibodies in 
NSCLC and lung tissues, to ensure the proper staining with these antibodies.[13,14] 
Validation on transfected cell lines with positive and negative controls has previously been 
published by others.[13,14] 
4.4 Microscopic evaluation of staining 
Manual evaluation of staining is time consuming and semi-quantitative. Automated 
systems have been applied and are commercially available. But such systems render separate 
assessment of subcellular staining difficult, e.g. cytoplasmic vs nuclear. They also exclusively 
score staining intensity of the whole core which makes scoring of distinct tissue 
compartments impossible, e.g. tumor vs stroma. From the beginning we aspired to use 
commercially available automated equipment, but the results were not satisfying.  A major 
drawback was that the machine could not reliably distinguish tumor from stroma and as many 
cores in our TMA contain a mix of neoplastic cells and stromal cells we were obliged to use 
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manual scoring. To minimize subjectivity all cores were scored by two trained pathologists. 
Before initiating scoring we reviewed the staining with controls again for quality reassurance, 
we agreed on what compartments to score, we agreed on the semiquantitative scale and we 
agreed on illustrative examples of the different scores. In IHC studies several scoring scales 
have been utilized. Every scoring system should have stratification for no expression and high 
expression as a potential clinical significance will show statistical significance between these 
two subgroups. Several scoring systems score the percentage of positive tumor cells as well 
and calculate a combined score of intensity and percentage of positive cells(136), like the 
Allred score(137) and the H-score developed by McCarthy.(138) Both for GLUT1 and CAIX 
a combined score could be meaningfully calculated due to heterogeneity in expression within 
the tumor. However, this combined score did not result in any significant change of our 
results. A simple intensity score was therefore used for all published results. 
Each anonymized core was scored independently, semiquantitatively and 
simultaneously by our pathologists by light microscopy. Only viable parts were scored and 
even though many cores comprised of both tumor and tumor stroma, only one entity was 
scored at a time. In stroma, we scored all non-neoplastic cells as a whole and did not differ 
between cells of different origins. 
For all of our antibodies there was a multilevel intensity of staining. If possible we 
tried to score the dominant intensity in tumor and stroma according to the four level scale; 0 = 
negative, 1 = weak, 2 = intermediate and 3 = strong. The intensity was scored in the cell 
compartment with significant scorable expression and where expression was anticipated 
according to previous publications and/or protein function. An exception was the HIFs where 
we anticipated more nuclear staining. Due to the low number of cores with a clear nuclear 
staining we scored the cytoplasmic expression. In stroma, density was scored as; 1 = low, 2 = 
intermediate, 3 = high. Throughout scoring procedures, the oncologist entered the scoring 
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results directly into a excel worksheet and a mean score was calculated for the duplicate cores 
for each individual. Interindividual variability with respect to IHC-scoring was evaluated on 
the current material in a previous paper (r = 0.95, range 0.93-0.98).(139) See Table 7 for 
details regarding expression and scoring. 
4.5 Determination of cut-off values  
The most frequently used analytical strategy for TMA-studies is subdivision into 
subgroups based on expression data. Dichotomization into high- and low-groups is easy if 
expression is only present or not. If, like in our studies, there is a multilevel or even 
continuous scale, cut-off points are not predefined. Some have used the mean expression and 
others have tried different cut-off points and then reported on the split giving the most 
significant difference in outcome between the high- and low-groups. The advantage of the 
mean is the lower risk of false positive results (Type 1 error) and it might even be easier to 
reproduce the results by other groups. The disadvantage by using the mean in stead of the 
most significant cut-off is that the mean cut-off is probably not the biologically important cut-
off and the risk of false negative results increases (Type 2 error). A balance of the two 
important risks of errors is the best. A way to circumvent the drawbacks of the use of the most 
significant cut-off is to use the hypothesis-generating results from a study with the use of the 
most significant cut-off in a subsequent independent hypothesis-testing study.(140) In our 
studies we have consistently used the most significant cut-offs, while trying to secure large 
enough subgroups. Therefore, independent validation of our hypothesis generating results 
would be of great value. Several high-impact journals like Clinical Cancer Research 
explicitly now want retrospective biomarker studies to include a validation study 
(http://clincancerres.aacrjournals.org/site/misc/journal_ifora.xhtml). We have therefore started 
to collaborate with another research group with TMAs for another cohort of NSCLC patients. 
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4.6 Statistical analysis 
The dimension of the patient cohort was estimated with disease-specific survival 
(DSS) as the primary endpoint. The entered criteria (into PASS 2002, Number Cruncher 
Statistical systems, Kaysville, UTAH) were: 1) At least 50% increase in hazard ratio resulting 
from the presence of a biomarker was assumed to represent a clinically significant effect; 2) 
The 5-year DSS for stage I-IIIA NSCLC patients around 60%; 3) The frequency of a 
biomarker around 35%. 
The statistical analyses were done using the versions 15.0, 16.0, 17.0.0 packages from 
SPSS (Chicago, IL). The χ2 test and Fishers exact tests were used to examine the associations 
between molecular marker expressions and the clinicopathological markers. r-values are the 
Spearman’s rank correlation coefficient. Survival curves, according to marker expressions, 
were drawn using the Kaplan-Meier method, and the statistical significance between survival 
curves was assessed by the log-rank test. The survival curves were terminated at 120 months 
in Paper 1 and 146 months in paper 2 and 3, due to less than 10% of patients at risk after this 
point. The chosen endpoint, DSS, was calculated from time of surgery to time of lung cancer 
death.  
In order to assess the independent value of the tested biomarkers on DSS in presence 
of established variables, we used the Cox proportional hazard model for multivariate analyses. 
For all three papers, all significant variables (both biomarker and clinicopathological markers) 
from the univariate analyses were entered into the multivariate analyses in a backward 
stepwise Cox regression analysis with a probability for stepwise entry and removal at 0.05 
and 0.10, respectively. A P < 0.05 was considered statistically significant for all analyses. In 
subgroup multivariate analyses all variables were again tested for significance in a univariate 
analysis and only the significant ones in that subgroup were entered in the subgroup 
multivariate analyses. In Paper 1 a multivariate analysis was done for the whole cohort and 
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for the two dominant histological subgroups, AC and SCC. For Paper 2 the multivariate 
analysis was done for the whole cohort (Model 1) and for the subgroup of patients with high 
Ang-2 expression (Model 2). In Paper 3 the multivariate analysis was done for the whole 
cohort for both Model 1 and 2, but for Model 2 the biomarkers were entered as a co-
expression variable. The co-expression variable, including all of the four HIF hydroxylases, 
was stratified by the number of HIF hydroxylases demonstrating high expression. All 
multivariate analyses respected the rule-of-thumb with a minimum of five events (lung cancer 
deaths) pr entered variable.   
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5 MAIN RESULTS 
5.1 Patient characteristics  
Demographic, clinical and histopathological variables are shown in Table 5. The most 
recent (third) DSS update was done in January 2011, but was not used for the papers in this 
thesis. The results herein are from the update in November 2008 where 99 patients of the 335 
included patients were still alive and 137 patients were dead of lung cancer (DSS event). The 
median follow-up was 86 months (range 48-216) and the median patient age was 67 years.   
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Table 5: Patient characteristics and prognostic clinicopathological variables for disease-
specific survival as updated in November 2008. P-values represent the log-rank test for 











Age     0.34 
     ≤ 65 years 156 47 83 55  
     > 65 years 179 53 NR 60  
Sex     0.20 
     Female 82 25 190 63  
     Male 253 75 83 56  
Smoking     0.23 
     Never 15 5 19 43  
     Current 215 64 NR 60  
     Former  105 31 71 54  
Performance status     0.013 
     PS 0 197 59 NR 63  
     PS 1  120 36 64 52  
     PS 2 18 5 25 33  
Weight loss     0.71 
     < 10% 303 90 127 58  
     > 10% 32 10 98 57  
Histology     0.08 
     SCC 191 57 NR 66  
 AC 113 34 54 45  
     LCC 31 9 98 56  
Differentiation     < 0.001 
     Poor 138 41 47 47  
     Moderate 144 43 190 64  
     Well 53 16 NR 68  
Surgical procedure     0.004 
     Lobectomy + Wedge* 243 73 190 61  
     Pneumonectomy 92 27 37 47  
Pathological stage     < 0.001 
     I 157 47 190 71  
     II 136 40 61 51  
     IIIa 42 13 17 23  
Tumor status     < 0.001 
     1 85 25 190 74  
     2 188 56 84 57  
     3 62 19 25 36  
Nodal status     < 0.001 
     0 232 69 190 66  
     1 76 23 35 43  
     2 27 8 18 18  
Surgical margins     0.29 
     Free 307 92 190 58  
     Not free 28 8 47 47  
Vascular infiltration     < 0.001 
     No 284 85 190 58  
     Yes 51 15 27 32  
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5.2 Overview of biomarkers and their expression 
An overview of biomarkers in our studies and their expression is given in Table 6 
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Table 6: Expression and scoring of biomarkers 






Scoring of tumor 
intensity 










minor nuclear (10%) 
with accentuated 
cytoplasmic staining 
Cytoplasmic 0 = negative 
1 = weak 
2 = intermediate 
3= strong 
No 0 = negative 
1 = weak 








some nuclear, but at 
even lower frequency 
Cytoplasmic As HIF1α No As HIF1α As HIF1α 
LDH5 Mainly 
homogenous 
Cytoplasmic Cytoplasmic As HIF1α No As HIF1α As HIF1α 
GLUT1 Heterogeneous and 
homogenous 
Membrane Membranous As HIF1α Yes, but 
results not 
reported. 
Only expressed in 
two cores 





membrane Membranous As HIF1α Yes, but 
results not 
reported. 
No stromal cell 
expression 
No stromal cell 
expression 
Ang-1 Homogenous Mainly cytoplasmic Cytoplasmic As HIF1α No As HIF1α As HIF1α 
Ang-2 Mainly 
homogenous 
Mainly cytoplasmic Cytoplasmic As HIF1α No As HIF1α As HIF1α 
Ang-4 Homogenous Exclusively cytoplasmic Cytoplasmic As HIF1α No As HIF1α As HIF1α 
Tie-2 Mainly 
homogenous 





Cytoplasmic As HIF1α No Not scored due to 
low-level staining 
in minority of cells 
Not scored due to 
low-level staining in 





Cytoplasmic As HIF1α No Not scored due to 
low-level staining 
in minority of cells 
Not scored due to 
low-level staining in 







Cytoplasmic As HIF1α No Not scored due to 
low-level staining 
in minority of cells 
Not scored due to 
low-level staining in 





Cytoplasmic As HIF1α No Not scored due to 
low-level staining 
in minority of cells 
Not scored due to 
low-level staining in 
minority of cells 
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5.3 Paper 1, HIFs and HIF targets 
This study aimed to explore the prognostic impacts of the hypoxic markers HIF1α, 
HIF2α, and the related metabolic markers GLUT1, LDH5 and CAIX in NSCLC as a whole 
and in histological subgroups. We were able to assess expression profiles of these markers 
both in tumor and stroma, with the exception of stromal expression for CAIX and GLUT1. 
Expression profiles are listed in Table 6. 
 
5.3.1 Correlation between markers 
There was a strong correlation between the stromal expression of HIF2α and LDH5 (r 
= 0.41, P < 0.001). Otherwise there were no relevant correlations (r ≥ 0.2) between the 
molecular markers. Between clinicopathological variables and molecular markers, the only 
highly significant correlation was between high tumor expression of GLUT1 and squamous 
cell histology (r = 0.37, P < 0.001). A weak, although significant correlation was observed 
between increasing T stage and high tumor cell HIF1α expression (r = 0.15, P = 0.005).  
 
5.3.2 Univariate analyses 
Among the examined molecular markers, high tumor cell expression of HIF1α (P < 
0.001) and GLUT1 (P = 0.013) and low stromal cell expression of HIF1α (P = 0.028), HIF2α 
(P = 0.001) and LDH5 (P = 0.11) correlated significantly with a poor DSS. CAIX expression 
did not have any significant impact on survival.  
For the SCC subgroup, poor differentiation (P < 0.001) and increase in pathological 
stage (P < 0.001), T-status (P = 0.008) and N-status (P < 0.001) were significant 
clinicopathological prognostic indicators for poor DSS. Among the molecular markers, high 
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tumor cell expression of HIF1α (P = 0.001) and low stromal cell expression of HIF1α (P = 
0.009) and HIF2α (P = 0.005) were significant prognosticators for a poor DSS. 
Among AC patients, significant clinicopathological prognostic indicators for a poor 
DSS were poor WHO performance status (P < 0.001), weight loss (P = 0.025), poor 
differentiation (P = 0.008), advanced surgical procedure (Pulmenectomy, P = 0.000), increase 
in pathological stage (P = 0.006), increased N-status (P < 0.001) and vascular infiltration (P = 
0.017). Regarding molecular markers, high tumor cell expression of GLUT1 (P = 0.01) and 
low stromal cell expression of LDH5 (P = 0.03) correlated significantly with a poor DSS. In 
the subgroup of patients (n = 55) administered postoperative adjuvant radiotherapy, only 
tumor HIF1α expression tended to be associated with a poor prognosis (P = 0.07). 
5.3.3 Multivariate analyses 
For all NSCLC patients, higher T-status (P = 0.004), higher N-status (P = 0.001), 
vascular infiltration (P = 0.03), high tumor cell expression of HIF1α (HR = 2.3, CI 95% 1.3-
4.1, P = 0.003) and GLUT1 (HR = 2.0, CI 95% 1.1-3.4, P = 0.02) and low stromal expression 
of HIF1α (HR = 1.8, CI 95% 1.3-4.1, P = 0.003) and HIF2α (HR = 1.8, CI 95% 1.2-2.8, P = 
0.006) were independent significant prognosticators for a poor DSS. 
In the SCC subgroup, higher T-status (P = 0.009), poor differentiation (P = 0.001), 
high tumor cell expression of HIF1α (HR = 3.3, CI 95% = 1.7-6.6, P = 0.001) and low stromal 
cell expression of HIF1α (HR = 2.1, CI 95% 1.2-3.7, P = 0.008) and HIF2α (HR = 2.3, CI 
95%, 1.3-4.4, P = 0.005) were independently and significantly associated with a poor DSS.  
In the AC subgroup, higher N-status (P < 0.001), poor WHO performance status (P < 
0.001), vascular infiltration (P=0.003), high tumor expression of GLUT1 (HR1.9, CI 95%, P 
= 0.046) and low stromal expression of LDH5 (HR = 2.3, CI 95%, P = 0.03) were 
independently associated with a poor DSS. 
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5.4 Paper 2, Angiopoietins and their receptor 
As angiopoietins are being targeted in ongoing clinical cancer trials, we aimed to 
evaluate the prognostic relevance of all angiopoietins, and their receptor Tie-2 in tumor and 
stromal compartments of NSCLC tissues from our large unselected cohort of NSCLC 
patients. Based on the proposed interplay between VEGF-A and angiopoietins, we also 
examined if the angiopoietins influenced the prognostic impact of VEGF-A expression. Data 
regarding VEGF-A expression have previously been published by our group.(139) Expression 
profiles are listed in Table 6. 
5.4.1 Correlations 
Regarding associations between molecular markers and clinicopathological variables, 
we found that high tumor cell expression of Ang-4 correlated to histology (r = 0.19, P = 
0.003), as it was more expressed in the squamous histology subgroup. Among examined 
molecular markers we found tumor cell expression of Ang-4 and Ang-1 to correlate 
moderately (r = 0.18, P = 0.001). Further, high tumor cell Ang-2 expression correlated to high 
tumor cell VEGF-A expression (r = 0.15, P = 0.007). 
5.4.2 Univariate analyses 
When assessing associations between molecular markers and disease-specific survival 
(DSS), we observed high tumor cell expression of Ang-4 (P = 0.046) as well as high stromal 
cell expression of Ang-4 (P = 0.009) and Ang-2 (P = 0.017) to be associated with a favorable 
DSS. For tumor cell Ang-2 expression alone there was no influence on survival. The 
favorable impact of high tumor cell Ang-4 expression was most prominent for subgroups of 
patients below 65 years (P = 0.002), males (P = 0.027), squamous cell histology (P = 0.038), 
nodal status 1 (P = 0.007) and those without vascular infiltration (P = 0.015). For Tie-2 and 
Ang-1 expression there was no association with DSS. 
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There was a profound survival impact of high tumor cell VEGF-A expression, but 
only in patients with concomitantly high Ang-2 tumor cell expression (P<0.001). At low Ang-
2 expression, tumor cell expression of VEGF-A had an insignificant prognostic impact (P = 
0.078).  
5.4.3 Multivariate analyses 
In model 1, where all patients were assessed, low stromal Ang-4 (HR = 1.47, CI 95% 
1.02–2.11, P = 0.04),  low stromal Ang-2 expression (HR = 1.88, CI 95% 1.15–3.08, P = 
0.012) and high tumor cell expression of VEGF-A (HR = 1.49, CI 1.04–2.14, P = 0.029) were 
significant independent prognosticators for poor DSS in addition to several 
clinicopathological variables (higher T status, P<0.001; higher nodal status, P<0.001; poor 
performance status, P = 0.013; vascular infiltration; P = 0.011; poor differentiation, P = 
0.033). High tumor cell expression of Ang-4 did not reach statistical significance (P = 0.15) 
with respect to prognosis after adjustment. 
In model 2, only patients with high tumor cell expression of Ang-2 were assessed (N = 
88). In this subgroup, high tumor cell expression of VEGF-A mediated an independent and 
strong negative prognostic effect (HR = 6.43, CI 95% 2.46–16.79, P<0.001). As did the 
following clinicopathological variables: positive nodal status (P = 0.003), reduced 
performance status (P = 0.024) and poor differentiation (P = 0.034). 
 
5.5 Paper 3, HIF hydroxylases 
We aimed to pioneer the first comprehensive prognostic impact evaluation of the HIF 
hydroxylases in this NSCLC cohort. Studies evaluating the clinical significance of these 
markers in malignancy are limited, even though they have a potential role as therapeutic 
targets. Due to available results from our previous NSCLC studies using this cohort, we were 
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able to examine correlations between the HIF hydroxylases and previously published markers 
of interest. 
5.5.1 Correlations 
There were no correlations between HIF hydroxylases and the clinicopathological 
variables, but weak correlations between some HIF hydroxylases were observed; PHD1 vs.. 
FIH (r = 0.14, P = 0.013) and PHD2 vs. FIH (r = 0.183, P = 0.001). When the HIF 
hydroxylases were compared with our tumor cell expression data from previously examined 
angiogenic markers(139;141-144), the following correlations were observed; PHD1 vs. 
VEGF-A (r = 0.27, P = < 0.001) and  PDGF-A (r = 0.23, P < 0.001); PHD2 vs. VEGFR3 (r = 
0.23, P < 0.001); FIH vs. VEGFR3 (r = 0.25, P < 0.001), Notch4 (r = 0.26, P < 0.001), HIF2α 
(r = 0.22, P < 0.001), LDH5 (r = 0.22, P < 0.001), Ang-1 (r = 0.21, P < 0.001), Ang-4 (r = 
0.24, P < 0.001), and Tie-2 (r = 0.22, P < 0.001).  
5.5.2 Univariate analyses 
We observed high tumor cell expression of all examined HIF hydroxylases (PHD1, P 
= 0.023; PHD2, P = 0.013; PHD3, P = 0.018; FIH, P = 0.033) to be significantly associated 
with poor survival. 
When assessing the co-expression between all the HIF hydroxylases, there was a 
significant additive pattern with a progressively worse survival by the increasing number (0-
4) of highly expressed HIF hydroxylases. 
 
5.5.3 Multivariate analyses 
In model 1, we found high tumor cell expression of the PHD2 (HR = 2.03, CI 95% 
1.20-3.42, P = 0.008) and PHD1 (HR = 1.45, CI 95% 1.01-2.10, P = 0.047) to be significant 
independent poor prognosticators for DSS, in addition to several clinicopathological variables 
(high T status, P < 0.001; high nodal status, P < 0.001; poor performance status, P = 0.001; 
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vascular infiltration; P = 0.002; poor differentiation, P = 0.006). High tumor cell expression of 
PHD3 (P = 0.058) and FIH (P = 0.15) did not, however, reach statistical significance. 
In model 2, we found a gradually increasing hazard ratio for lung cancer death in 
patients with an increasing number of highly expressed HIF hydroxylases in comparison to 
those without high expression levels. Patients with high tumor cell expression of all four HIF 
hydroxylases had a HR of 6.48 (CI 2.23-18.8, P = 0.001) compared to patients without high 
expression of HIF hydroxylases. 
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5.6 Summary of prognosis data 
A summary of the prognostic impact mediated by the investigated markers is presented in 
Table 7 
 
Table 7: Summary of statistically significant prognosis data from the univariate, multivariate, 
subgroup and co-expression analyses published in Paper 1-3. Hazard ratios are only stated if 
significant at the P ≤ 0.05 level.  
Univariate 
analyses 
Multivariate analyses Biomarker 
Tumor Stroma Tumor Stroma 
Subgroup or co-
expression analyses 
HIF1α ↓ ↑ ↓ HR = 2.3 ↑ HR = 1.8 Only significant in SCC 
subgroup, HR tumor = 
3.3, HR stroma = 2.1   
HIF2α NS ↑ NE ↑ HR = 1.8 Only significant in SCC 
subgroup, HR = 2.3 
LDH5 NS ↑ NE NS Only significant in AC 
subgroup, HR = 2.3 
GLUT1 ↓ NSc ↓ HR = 2.0 NE Only significant in AC 
subgroup, HR = 1.9 
CAIX 
 
NS NSc NE NE - 
Ang-1 
 
NS NS NE NE - 




↑ ↑ NS ↑ HR = 1.47 - 
Tie-2 
 
NS NS NE NE - 
PHD1 
 
↓ NSc ↓ HR = 1.45 NE 
PHD2 
 
↓ NSc ↓ HR = 2.03 NE 
PHD3 
 
↓ NSc NS NE 
FIH 
 
↓ NSc NS NE 
Patients with high tumor 
cell expression of all HIF 
hydroxylases had a very 








NS NA NE NA - 
↑ High expression in compartment associated to good prognosis, ↓ High expression in compartment associated to 
poor prognosis, NS = Not significant, NSc = Not scorable, NE = Not entered due to non-significance in 
univariate or not scorable expression in the compartment, NA = Not analyzed, SCC = Squamous cell carcinoma, 
AC = Adenocarcinoma, HR = Hazard ratio 
*Evaluation of expression not primarily part of this study, but assessed in subgroups of Ang-2 expression. 
Details regarding VEGF-A expression can be found in ref (139) 
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6 DISCUSSION 
6.1 A summary of strengths and weaknesses 
The strengths and weaknesses of this study have been discussed in more detail in the 
material and method sections (section 4). Summarized, strengths and weaknesses are 
presented in Table 8. 
Table 8: Strength and weaknesses of our study 
Weaknesses Strengths 
Lack of standardized tissue acquisition and fixation 
protocol  
Relatively large number of patients.  
Possibly reduced tissue representativity/heterogeneity 
due to small tissue samples (cores) 
Hardly any selection bias due to the fact that near all 
NSCLC stage I-IIIA patients are surgically treated in 
the region, and 90% of these were included 
No in-house validation of antibody specificity at our 
lab (mostly commercial antibodies) 
A comprehensive collection of vital clinical data 
No external positive controls in paper 1 and 2 and 
only one external positive control for one antibody in 
paper 3 (PHD1) 
The patient follow-up is extensive.  
 
Isotype control was not done for paper 1 and paper 3.  The tissue fixation technique has not been altered 
during the patient inclusion period 
Assessments of tissue staining is semiquantitative 
 
All included tissues were carefully reviewed by two 
experienced pathologists, bringing the stage 
classifications up to date 
Stroma was only assessed as a whole 
 
We have used few dedicated technicians for TMA 
assembly and IHC-procedures 
Optimal cut-offs were used which increases the risk of 
false positive results (Type 1 errors)  
Duplicate cores taken from preselected and marked 
areas on the tumor blocks 
Possibly most important, our results were not 
validated in other patient cohorts.  
Careful antibody selection and in-house testing was 
performed 
 Expression profiles for the different biomarkers were 
carefully compared to already published data 
 Appropriate positive controls were used where 
consistent positive tissue was known 
 The microscopic scoring for IHC staining was always 
done by two independent pathologists, blinded to 
outcome and each other’s scores 
 Optimal cut-offs reduce false negative results (Type II 
errors).  
 Appropriate and robust statistical analyses were 
performed, with main outcome being disease-specific 
survival.    
 We assessed protein expressions both in stromal and 
neoplastic cells 
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6.2 Paper 1 
Herein, we identified the tumor cell expression of HIF1α and GLUT1 to be 
independent prognosticators for poor survival, whereas stromal expression of HIF1α, HIF2α 
and LDH5 were prognosticators for a better survival. We observed a discrepancy between 
histological subgroups as the HIF results were significant in the SCC, but not in the AC 
subgroup. This observation was contrasted to the LDH5 and GLUT1 results, which were 
significant in the AC, but not the SCC subgroup. 
To explore hypoxia-related markers, HIFs and HIF responsive genes were obvious 
choices, although there were already several related studies in neoplasias, and also in NSCLC. 
See Table 9 for a summary of studies regarding these biomarkers and their prognostic 
relevance in NSCLC. To our knowledge, this is the largest study published in this research 
field, and the only study examining the prognostic impact of HIF and HIF-related marker 
expression in stroma. Two of the previous published studies were TMA-based while the 
others were whole slide studies. Which compartment of the cell to score has in general been 
fairly easy to determine. However, the HIFs have been scored both in the nucleus and 
cytoplasm. The nuclear scoring is biologically plausible as HIFs are known to exert their 
effects in the nucleus. We set out to do both, but less than 10% of cells had nuclear positivity 
and all cases with nuclear positivity had strong cytoplasmic staining. No other information 
was found by nuclear scoring than could not be detected by a high cut-off of cytoplasmic 
staining. In tumor, we chose a high cut-off score for HIF1α positivity. This cut-off score 
separated the subgroups best with respect to survival, and the high expression group had in 
general also nuclear staining. Corroborating our findings, high tumor cell expression of 
HIF1α has in previous studies been associated with a poor survival across a wide range of 
cancers. In NSCLC, however, none of the previous studies found tumor cell expression of 
HIF1α to have a prognostic impact independent of clinicopathological or other factors.(59) 
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This is in contrast to our study. Regarding two studies studying tumor cell expression of 
HIF1α and HIF2α in NSCLC, both identified HIF2α as an independent prognostic 
factor.(53;145) No clear explanation for this divergent finding can be provided. The 
association between high tumor cell expression of HIFs and poor survival has been ascribed 
to their role as endogenous markers of hypoxia and tumor hypoxia, which is associated to 
poor survival.(146) However, their role as endogenous markers of hypoxia is disputed.(147)  
Hitherto, we are alone in studying the stromal expression of HIFs. We found an 
inverse prognostic impact between expression of HIFs in tumor and stroma. In stroma, high 
HIF expression appeared to render a beneficial prognostic impact. An improved prognosis for 
patients with a high expression of various markers in the stroma has been a consistent finding 
in our studies.(139;143;144;148-154) We suspect that the in-situ stromal immunity may be, at 
least in part, responsible for these findings. We have previously reported high densities of 
CD4+ and CD8+ lymphocytes in stroma to be strong independent positive prognosticators in 
NSCLC, and that lymphocytes constitute a large proportion of NSCLC stromal cells.(153) 
This may, however, not be the whole story as correlations between lymphocytes and hypoxic 
markers are only weak to moderate, though present. In addition, some reports have suggested 
that HIF1α activity in T-cells may protect hypoxic cancerous tissues from anti-tumor T 
cells.(155) Moreover, HIFs in the stroma had a highly significant prognostic impact in the 
SCC subgroup, but no prognostic relevance in the AC subgroupgroup. We observed that the 
SCC subgroup had a marginally higher percentage high expression cases than AC. This can 
only partly explain some of the difference. On the other hand, SCC tumors are known to be 
more hypoxic than AC tumors.    
Among the three available GLUT1 studies in NSCLC(156-158) only Minami et 
al.(158) identified GLUT1 as an independent prognostic factor. The larger, but older, study by 
Younes published only prognostic data regarding the co-expression of GLUT1 and 
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GLUT3.(156) Extensively expressed in tumor cells, GLUT1 is an important player in cancer 
metabolism. Due to the high prevalence of high GLUT1 tumor cell expression in SCC, we 
only detected a statistically trend for reduced survival due to the small number of low 
expression cases. In ACs we found a significant poor prognostic influence by high tumor cell 
GLUT1 expression. There was also a slightly larger absolute difference in 5-year survival in 
the AC when compared to the SCC subgroup. A larger prognostic impact in AC subgroup 
seems a proper conclusion.
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Table 9: Other IHC studies in NSCLC regarding biomarkers in Paper 1. Pubmed accessed 01.08.11 
Author Journal 








and localization  
Scoring and cut-off Univariate analyses Multivariate 
analyses 
Younes et al. Cancer 
1997 
GLUT1 289 ( 25% 
SCC, 60% 







scale 1-6. All tried, 
but negative vs >1% 
positive  
GLUT1 and GLUT3 
tested together, but 
probably GLUT1 
most important factor 




BJC 2001 HIF1α 
HIF2α 
108, T1-2, 
N0-1 ( 72 
SCC), 36 
AC) 







Combined score 1-4 High HIF1α (P = 
0.08) and HIF2α (P = 
0.008) associated 
with poor overall 
survival 














74 (38 SCC, 
26 AC, 6 
LCC, 4 
unspec) 
Stage I and 
II, male only 








HIF1α: % positive 
cells > mean were 
positive 
CAIX: positive if 
intensity>1, mean 
cut-off for % cells  
HIF1α: High HIF1α 
associated to poor 
survival 
CAIX: High % of 
positive cells 
associated to poor 




variable, high % 
of positive cells 
associated to poor 




BJC 2001 CAIX 107 (70 
SCC and 37 
AC) T1-2, 
N0-1 






% of positive cells High expression 
associated to poor 




were excluded (P 
= 0.02) 
Minami et al.  Lung 
Cancer 
2002 
GLUT1 47 (AC 
only), Stage 
1 





>10% were scored 
positive  
Positive expression 
associated to poor 
survival (P < 0.0001) 
Positive 
expression 
associated to poor 
survival (P < 
0.026)  
Lee et al. J Korean 
Med Sci 
2003 
HIF1 α 84 (45 SCC, 
39 AC), 
operable 






Sum of intensity (0-
3)and %positive (0-3) 
>2 





BJC 2003 LDH5  112 ( 76 
SCC and 36 





(>80%) was used as 
Both high 
cytoplasmic and high 







tumor only cut-off 
Nuclear, median 
(10% used as cut-off) 
nuclear expression 
was associated to 
poor overall survival 




Swinson et al. Int J 
Cancer 
2004 and 














stated  observer, 
Semiquantitative 
HIF1α: Nuclear 





HIF1α: % of positive 
cells. 5% (mean) cut-
off, but other tested 
(>60%) 
CAIX: pCAIX, pos 
or neg, mCAIX % of 
positive cells with 
quartile cut-offs, 
sCAIX density of 
staining 0-4  
HIF1α: High positive 
(>60% positive cells) 
was associated with 
poor survival. 
CAIX: High 
perinuclear and not 
membrane CAIX 
associated with poor 
survival 





Hirami et al. Cancer 
Letters 
2004 
HIF1α 80 (58 
adeno, 19 
SCC) 





intensity and % of 
positive cells (1-4) ≥3 
NS NS 
Nguyen et al. Eur J 
Radiol 
2007 
GLUT1 53 ( SCC 
19, AC 30) 




combination of % of 
positive cells and 
intensity  
NS to disease-free 
survival 
NA 
Hung et al. Thorax 
2009 




>50% positive cells 
 
High expression 
associated to poor 
survival (P = 0.005) 
Only co-
expression with 
TWIST and Snail 
was tested. 
Kayser et al. Diagn 
Pathol 
2010 
LDH5 269 (106 
SCC, 90 AC 
and 73 
LCC) 
TMA 1 observer? Cytoplasmic 
and/or nuclear 
tumor 
Mean (50%) used as 
cut-off. Scale 0-3 for 
intensity and % of 
positive cells. 
NS  NA 





80, AC 40, 
14 other), 
Stage I-III 











to poor survival (P = 
0.001) 
HIF1α: NA 
HIF2α:  High 
expression 
associated to poor 
survival. 
NA= Not assessed, WS = Whole slide, TMA = Tissue micro array, SCC = Squamous cell carcinoma, AC = Adenocarcinoma, NS = Not significant. One study regarding 
GLUT1 was in Chinese only and is not included in this table.(159)
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6.3 Paper 2 
Herein, we observed the tumor cell expression of Ang-4 to be a prognosticator for 
poor survival, but not when adjusted for other prognostic variables. In tumor stroma, high 
expression of Ang-4 and Ang-2 were independently associated with improved survival. When 
patient subgroups were stratified for high or low Ang-2 expression in tumor cells, we 
observed high tumor cell expression of VEGF-A strongly correlate to poor survival in the 
patients with high Ang-2 expression, but not for patients with low Ang-2 expression. 
Although Ang-4 expression has not been previously evaluated for prognostic impact, 
an improved prognosis following high tumor cell expression of Ang-4 is in accordance with 
an earlier functional in vitro study by Olsen and co-workers.(80) They observed Ang-4 to 
inhibit angiogenesis and reduce the elevated interstitial pressure induced by basic fibroblast 
growth factor (bFGF) and VEGF in small cell lung cancer tumor cells (GLC19). Recently 
these results have been contrasted by an observation where Ang-4 promoted glioblastoma 
progression in vitro by enhancing tumor cell viability and angiogenesis.(160) 
The prognostic impact of Ang-1, Ang-2 and Tie-2, has been investigated by other 
researchers. In a fairly large NSCLC study, utilizing IHC to examine the prognostic impact of 
Ang-1 and Ang-2, Tanaka et al. found that high Ang-2 expression in tumor was associated to 
poor survival.(134) Due to their heterogeneous staining intensity and low expression in 
endothelial cells, they were not able, however, to semiquantitatively evaluate the degree of 
Ang-1 or Ang-2 expression. This is in contrast to the experience by us and others.(131;161) In 
a smaller IHC study with early stage NSCLC, examining Ang-1 and Ang-2, Reinmuth et al. 
found high tumor cell expression of Ang-1, but not Ang-2 in tumor to be independently 
associated with a poor survival.(161) Using IHC and RT-PCR to examine the Ang-2 
expression in tumor, Takanami et al. found that high expression of Ang-2 prognosticated poor 
survival.(162) In other cancers, high expression of Ang-2 in tumor, examined by IHC, has 
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mostly been associated to a poor prognosis.(130;131;163-165). A balance of Ang-1/Ang-2 
expression has been found associated with survival for glioblastoma patients,(166) but not in 
patients with mammarian cancers.(167)  
We also examined the prognostic effects of Ang-2 and VEGF-A co-expressions in 
tumor cells since VEGF-A has been one of the most studied molecular marker of 
angiogenesis and the availability of targeted therapies towards VEGF-A. When Ang-2 co-
expressed with a high rather than low VEGF-A level, this combination led to a significantly 
worse 5-year survival (32%) with an HR of 6.43. These results are in accordance with the 
Tanaka study.(134) Besides, those with a concomitantly low VEGF-A and high Ang-2 
expression in tumor cells tended to a better survival compared with those with a low tumor 
cell Ang-2 expression. These results can be explained by the functional role of Ang-2, as it is 
known to destabilize the endothelium.(47) The plastic state triggered by Ang-2 can lead to 
new vessel growth or vessel regression, depending on the presence of factors such as VEGF-
A.(72) At low levels of VEGF-A, high Ang-2 levels may lead to vessel regression and a better 
prognosis. This is in accordance with a study by Huang and colleagues who detected that both 
over-expression of Ang-1 and administration of an Ang-1 agonist, induced a shift towards 
Tie-2 stimulation and protected tumors and vasculature from regression.(76) However, in a 
recent study by Hashizume and co-workers, they observed that inhibition of both Ang-2 and 
VEGF-A slowed tumor growth more effectively combined than inhibition of any one of 
them.(168) 
Considering our results, it may be speculated if cancers with a high tumor cell Ang-2 
expression are more susceptible to anti-VEGF-A treatment (e.g. bevacizumab). The predictive 
value of angiopoietins and their receptor has only been tested in serum and for effect of 
chemotherapy in NSCLC with an observation of no predictive value,(169) but for colorectal 
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cancer patients a low serum level of Ang-2 protein was associated with a better response rate 
of bevacizumab which is in contrast to our speculations.(170) 
In stroma, on the other hand, there are no previous studies examining the prognostic 
impact of these markers although stromal cells are the main expressors of angiopoietins.(171)  
In our TMA system systematic studies of tumor vessels could not be done due to the limited 
stromal tissue of only 0.6 mm in diameter from each patient. Nevertheless, the expression of 
Ang/Tie-2 markers has been investigated in the stromal compartment where the cross-talk 
between endothelial cells, fibroblasts, immunological cells and tumor cells are vital for 
angiogenesis.(47;171) Consistently, we found both Ang-4 and Ang-2 expression in stroma to 
be independently associated with an improved survival. Since these markers are known to 
exert opposite effects upon binding to Tie-2, the similar beneficial prognostic effect remains 
to be elucidated.
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Table 10: Other IHC studies in NSCLC regarding biomarkers in Paper 2. Pubmed accessed 01.08.11. 
Author Journal 








and localization  
Scoring and cut-off Univariate analyses Multivariate 
analyses 


















associated to poor 
survival (p = 0.027). 
VEGF-A and Ang-2 
co-expression 
associated to poor 
prognosis (P = 0.004) 
High Ang-2 
associated to poor 
survival (HR = 
1.46, P = 0.041) 







72, Stage I 
and II 





Combined score of 
intensity and percent, 
Median cut-off 
High Ang-1 
associated to poor 
survival ( P = 0.03) 
High Ang-1 
associated to poor 
survival (HR = 
2.5, P = 0.03) 
Unadjusted? 
Takanami et al. Oncology 
Reports 
2004 
Ang-2 77, curative 
resection 





Intensity High Ang-2 
associated to poor 
survival 
High Ang-2 
associated to poor 
survival 
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6.4 Paper 3 
In our final paper, using validated antibodies, we observed scorable expression of all 
HIF hydroxylases in tumor cells, but not in the stroma. HIF hydroxylases were observed, in 
general, to be poor prognosticators for NSCLC survival. PHD1 and PHD2 were independent 
negative prognostic factors in NSCLC. Moreover, there was an additive poor prognostic 
impact by the increasing number (0-4) of highly expressed HIF hydroxylases. 
A limited number studies have evaluated the protein expression of HIF hydroxylases 
in various cancers(172-180) including one in NSCLC.(181) Only three have assessed survival 
outcome of cancer in relation to expression of these HIF hydroxylases,(173-175) but none in 
NSCLC. In general, IHC-studies have found increased, but variable staining of PHDs and FIH 
in human cancers.(96) Corroborating previous studies, (173;174;176;177;180) we did not find 
the expected simplistic association between high HIF hydroxylase expression and low HIFα 
expression, or vice versa, as expected from earlier functional studies.(96). In comparison to 
the NSCLC study mentioned above,(181) the expression patterns in our TMA cores where 
similar, but nuclear expression was normally accompanied by a strong cytoplasmic 
expression. A few small studies in pancreatic cancers(174;175) and prostate cancer, (173) 
showed associations between HIF hydroxylase expression and reduced survival. A recent 
gene expression study in NSCLC reported that PHDs were expressed at higher levels in tumor 
tissue than adjacent normal tissue, but outcomes were not assessed.(182) 
The early functional studies on HIF hydroxylases identified them as downregulators of 
HIFα. The fact that high expression of HIF hydroxylases serve as poor prognosticators for 
DSS seemingly contradicts the canonical function as inhibitors of HIFα.(59) Several 
experimental studies have recently tried to elucidate essential roles of HIF hydroxylases in 
tumor progression. In line with our data, Henze et al. found that inhibition of PHDs 
significantly reduced glioblastoma cell survival and that PHD inhibition increased hypoxic 
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cell death as well as death induced by chemotherapeutic agents. Furthermore, the PHD/HIF 
regulatory axis was postulated as a novel therapeutic target to disable a tumor’s ability to 
adjust to hypoxic conditions and maintain cell survival.(176) Mazzone et al. did functional 
studies of the stromal role of PHD2 in tumorigenesis by implanting pancreatic tumors in 
immunocompromized PHD2+/- mice.(183) Surprisingly, the heterozygous deficiency of 
PHD2 led to improved endothelial lining, vessel maturation, tumor perfusion and oxygenation 
, and a subsequent inhibition of tumor cell invasion, intravasation and metastasis. The 
experimentally reduced available level of PHD2 in the host actually seemed to reduce the 
malignancy of implanted tumors. In accordance, a recent publication by Ameln et al. showed 
that inhibition of PHD2 in osteosarcoma and melanoma tumor cells actually stimulated vessel 
formation, but resulted in a profound reduction of tumor growth through the TGFβ 
pathway.(184) Besides, Ginouves et al. found that chronic hypoxia (24 h to 7 days) increased 
the pool of PHDs and overactivated all three isoforms thereby “desensitizing” HIFα and 
protected cells from necrosis.(185) Desensitizing HIFα proved to be required since all 
experimental cells died if HIF1α expression was not reduced during chronic hypoxia. Chan et 
al. found that tumors grew dramatically faster than control tumors and that PHD2 loss also 
induced angiogenesis and recruitment of bone marrow-derived cells in a model of colon 
carcinoma xeongrafts with decreased PHD2 expression.(186) In pancreatic cancer, Su et al. 
reported that PHD3 overexpression mediated tumor cell growth and invasion,(179) whereas 
overexpression of PHD1 was shown by Erez et al. to inhibit tumor growth.(187) The studies 
so far do not give us a clear functional explanation of the HIF hydroxylases in cancer. To 
quote Jokilehto and Jaakkola in a recent review “given the uncertainties in specific PHD 
function, their role in cancer is inconclusive at the best”.(96)  
As high cellular levels of HIF hydroxylases seem to be important in the malignant 
phenotype, they may qualify as potential therapeutic targets in NSCLC. Due to the basic 
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understanding of HIF hydroxylase functions, Nagel et al. recently proposed inhibition of 
HIFα through activation of PHDs.(188) But if PHDs hold a position in disease progression, 
consistent with our findings, it would rather be a target of inhibition. Although several 
inhibitors of HIF hydroxylases are known, there are presently no registered ongoing studies 
on such inhibitors in cancer registered on (www.clinicaltrials.gov accessed 05.09.11). 
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7 CONCLUSIONS AND IMPLICATIONS FOR FURTHER 
RESEARCH  
Hypoxia is a common phenotype in NSCLC and leads to adaptive cell changes in 
surviving cancer cells. Angiogenesis is one of the most important adaptive phenotypes 
employed by hypoxic tumors involving central angiogenic markers like angiopoietins (Angs), 
vascular endothelial growth factors (VEGFs) and their receptors.  
Hypoxia is associated to chemo- and radio-resistance and ways to reverse or exploit 
hypoxia in cancer have been a focus for cancer research for more than five decades. Hypoxia 
in actual patient tumors has been difficult to investigate in routine clinical practice, so efforts 
have been made to identify markers of hypoxia. Hence, the term endogenous markers of 
hypoxia, has been used for hypoxia related biomarkers. Hypoxia induced factors (HIFs), their 
subsequent target genes and angiogenic markers are at the heart of adaptive cancer cell 
mechanisms. Their prognostic or predictive roles will hopefully improve the understanding of 
tumor biology, improve patient prognostication and facilitate personalized and more optimal 
therapy as well as assisting future drug developments and drug trials. 
In this thesis we have studied the hypoxia inducible factors (HIFs), several of their 
target genes (CAIX, LDH5, GLUT1 and HIF hydroxylases) and important players in 
angiogenesis (angiopoietins and their receptors). Among these we have identified important 
independent prognostic factors in tumor and stromal tissue as well as finding these results to 
be associated to important histological subgroups. The co-expression of oxygen sensors in 
NSCLC tumors was observed to be a strong independent variable to effectively separate 
patients with regard to prognosis.  
Our study is not perfect and our weakest spots are the lack of validation cohorts and 
sparse in-house antibody validation. Hitherto, our NSCLC cohort is, however, one of the 
largest contributing in the quest for useful biomarkers. To our knowledge, it is the only 
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prognostic study in NSCLC evaluating prognosis through stromal marker expression. Finally, 
a lot of effort has been put into quality assuring measures.  
The findings herein will hopefully be tested in prospective studies. We also hope that 
the evaluated biomarkers will gain attention with respect to future clinical trials targeting 
these molecules in cancer so that also the predictive role of these biomarkers can be 
elucidated. We are increasingly collaborating with other research groups with TMAs in 
NSCLC so that validation of each others biomarker results can be achieved. Our group is also 
prospectively collecting fresh NSCLC tumor tissues for future studies, are establishing short 
term primary cell lines for molecular characterization and interventions, and we have recently 
started exploring the emerging field of microRNAs in NSCLC.  
We are also broadening our research field by implementing our established methods 
into new tumor origins like prostate cancer. The years ahead will be demanding in work, but 
rewarding in new questions and answers. 
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